Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy

Journal of Drug Targeting

Volumn 15, Issue 7-8, 2007, Pages 546-551

  Fisher, Kerry D ^a   Green, Nicola K ^b   Hale, Ashley ^b   Subr, Vladimir ^c   Ulbrich, Karel ^c   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Hybrid Systems Ltd   (United Kingdom)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Cancer; Passive targeting; Polymer coated virus; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LUMINESCENCE; MEDICAL DECISION MAKING; MESOTHELIOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPORTER GENE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PERMEABILITY; POLYMERS; TRANSGENES;

EID: 34547697008     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701501014     Document Type: Article

References (18)

1. Fisher, KD, Stallwood, Y., Green, NK, Ulbrich, K., Mautner, V. and Seymour, LW (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther, 8, pp. 341-348.
2. Gabizon, A., Price, DC, Huberty, J., Bresalier, RS and Papahadjopoulos, D. (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res, 50, pp. 6371-6378. 1990
3. Gabizon, AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res, 52, pp. 891-896.
4. Gabizon, AA, Shmeeda, H. and Zalipsky, S. (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res, 16, pp. 175-183.
5. Greber, UF, Webster, P., Weber, J. and Helenius, A. (1996) The role of the adenovirus protease on virus entry into cells. Embo J, 15, pp. 1766-1777.
6. Green, NK, Herbert, CW, Hale, SJ, Hale, AB, Mautner, V., Harkins, R., Hermiston, T., Ulbrich, K., Fisher, KD and Seymour, LW (2004) Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther, 11, pp. 1256-1263.
7. Liu, TC, Galanis, E. and Kirn, D. (2007) Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Prac Oncol, 4, pp. 101-117.
8. Maeda, H., Seymour, LW and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem, 3, pp. 351-362.
9. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46, pp. 6387-6392.
10. McCormick, F. (2003) Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther, 2, pp. S157-S160.
11. Parato, KA, Senger, D., Forsyth, PA and Bell, JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer, 5, pp. 965-976.
12. Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1989) Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials, 10, pp. 335-342.
13. Seymour, LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst, 9, pp. 135-187.
14. Seymour, LW, Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K. and Duncan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer, 31, pp. 766-770.
15. Seymour, LW, Ulbrich, K., Steyger, PS, Brereton, M., Subr, V., Strohalm, J. and Duncan, R. (1994) Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer, 70, pp. 636-641.
16. Seymour, LW, Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol, 39, pp. 1125-1131.
17. Thorne, SH, Hermiston, T. and Kirn, D. (2005) Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin Oncol, 32, pp. 537-548.
18. Vasey, PA, Kaye, SB, Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, AH, Murray, LS, Hilditch, TE and Murray, T. (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res, 5, pp. 83-94.